On April 14, 2026 MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical-stage genetic medicines company, reported it will host a conference call and webcast to present 3-year data from the long-term follow-up of patients in the Phase 1 study of AAV-hAQP1 for the treatment of persistent grade 2/3 moderate to severe radiation-induced xerostomia (RIX) on Thursday, April 16, 2026, at 8:00 a.m. ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will include:
Three-year data from the long-term follow-up of the patients in the open-label Phase 1 AQUAx clinical study.
This data will include:
PRO Xerostomia Questionnaire (XQ) data out to 3 years post treatment with AAV-hAQP1 for both bilateral and unilateral cohorts
Objective Unstimulated Whole Saliva Flow Rate (UWSFR) data out to 3 years
Full cohort data, as well as individual patient data out to 3 years for both the XQ and UWSFR
Study Investigator discussion of disease burden, patient experience, and treatment administration
Commercial opportunity
A question-and-answer session will follow the formal presentation.
To register and attend the event, please click here.
A live webcast of the call, as well as a replay, will be available on the Investors page of the Company’s website at www.investors.meiragtx.com/.
About the Phase 1 AQUAx Clinical Trial
The Phase 1 AQUAx clinical trial is an open-label, non-randomized, dose escalation trial designed to evaluate the safety of MeiraGTx’s investigational gene therapy AAV-hAQP1 when administered via Stensen’s duct to one or both parotid glands in patients who have been diagnosed with grade 2 or 3 radiation-induced xerostomia and who have remained cancer-free for at least five years (or at least two years if HPV+) after receiving radiation treatment for head and neck cancer. Primary endpoint of the trial is safety, with efficacy endpoints including patient-reported measures of xerostomia symptoms and the evaluation of the change in parotid gland salivary output after treatment with AAV-hAQP1. The 12-month data have been released and presented publicly. Patients treated in the Phase 1 AQUAx study are followed for 5 years after the one-time administration of AAV-hAQP1.
(Press release, MeiraGTx, APR 14, 2026, View Source [SID1234664391])